{"ATC Code":"A04AA01","Abbreviation":"","Aliases":["Zofran ODT","Zudan","Zuplenz","116002-70-1","Ondansetron Injection","GR 38032X","GR 38032","A04AA01","EUR-1025","1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one"],"Biological Half-Life":"The half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and could be extended to 6-8 hours in the elderly.","CAS":"99614-02-5","ChEBI":"CHEBI:7773","ChEMBL":"CHEMBL46","ChemicalClasses":["phenethylamine"],"Chirality":"racemic","Color/Form":"Crystals from methanol","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":2,"Upper":4},"Heavy":{"Lower":4,"Upper":6},"Light":{"Lower":2,"Upper":2},"Strong":{"Lower":4,"Upper":4},"Threshold":{"Lower":1,"Upper":2}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antiemetics; Gastrointestinal Agents; Serotonin Antagonists; Serotonin 5-HT3 Receptor Antagonists","Drug Indication":"In the adult patient population: i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and - the prevention and treatment of postoperative nausea and vomiting  ii) intravenously administered ondansetron injection formulations are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and - the prevention and treatment of postoperative nausea and vomiting  In the pediatric (4-18 years of age) patient population: i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting, ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger, iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting  In the geriatric (\u003e65 years of age) patient population: i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population","Drug Warnings":"Because of the risk of QT-interval prolongation, ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, congestive heart failure, or bradyarrhythmias and in those receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to IV administration of ondansetron. Because effects of ondansetron on the QT interval are dose related, use of single IV doses exceeding 16 mg should be avoided. Patients receiving ondansetron should be advised to seek immediate medical care if feelings of faintness, lightheadedness, irregular heartbeat, shortness of breath, or dizziness occur.","DrugClasses":[],"European Community (EC) Number":"619-449-4","FDA Pharmacological Classification":"4AF302ESOS","FullSalts":["Ondansetron hydrochloride"],"HMDB ID":"HMDB0005035","HeavyAtomCount":22,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antiemetics; Gastrointestinal Agents; Serotonin Antagonists; Serotonin 5-HT3 Receptor Antagonists","IUPACName":"9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one","Impurities":["1,2,3,9-tetrahydro-9-methyl-3-methylene-4h-carbazol-4-one"],"InChI":"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3","InChIKey":"FELGMEQIXOGIFQ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)","Melting Point":"231-232 °C","MolecularFormula":"C\u003csub\u003e18\u003c/sub\u003eH\u003csub\u003e19\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"293.4 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Ondansetron is a highly specific and selective serotonin 5-HT\u003csub\u003e3\u003c/sub\u003e receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors,. The serotonin 5-HT\u003csub\u003e3\u003c/sub\u003e receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema,. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents, suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract,. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT\u003csub\u003e3\u003c/sub\u003e receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting,.  Moreover, the effect of ondansetron on the QTc interval was evaluated in a double-blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron was tested at single doses of 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, prolongation of the Fridericia-corrected QTc interval (QT/RR0.33=QTcF) was observed from 15 min to 4 h after the start of the 15 min infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 19.6 (21.5) msec at 20 min. At the lower tested dose of 8 mg, QTc prolongation was observed from 15 min to 1 h after the start of the 15-minute infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 5.8 (7.8) msec at 15 min. The magnitude of QTc prolongation with ondansetron is expected to be greater if the infusion rate is faster than 15 minutes. The 32 mg intravenous dose of ondansetron must not be administered. No treatment-related effects on the QRS duration or the PR interval were observed at either the 8 or 32 mg dose.  An ECG assessment study has not been performed for orally administered ondansetron. On the basis of pharmacokinetic-pharmacodynamic modelling, an 8 mg oral dose of ondansetron is predicted to cause a mean QTcF increase of 0.7 ms (90% CI -2.1, 3.3) at steady-state, assuming a mean maximal plasma concentration of 24.7 ng/mL (95% CI 21.1, 29.0). The magnitude of QTc prolongation at the recommended 5 mg/m2 dose in pediatrics has not been studied, but pharmacokinetic-pharmacodynamic modeling predicts a mean increase of 6.6 ms (90% CI 2.8, 10.7) at maximal plasma concentrations.   In healthy subjects, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. Multiday administration of ondansetron has been shown to slow colonic transit in healthy subjects. Ondansetron has no effect on plasma prolactin concentrations.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":4595,"Record Description":["Ondansetron is a member of carbazoles.","A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.  Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis.  The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.","Ondansetron is a Serotonin-3 Receptor Antagonist. The mechanism of action of ondansetron is as a Serotonin 3 Receptor Antagonist.","Ondansetron is a carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","ONDANSETRON is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 35 investigational indications.","Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.","A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.","See also: Ondansetron Hydrochloride (has salt form).","Ondansetron is a member of carbazoles.","LiverTox|Gastroinestinal|Antiemetic|5HT-3 receptor antagonist"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Ondansetron","Name":"Ondansetron","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q410011","Name":"Ondansetron","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27270680","Name":"(-)-Ondansetron","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00904","Name":"Ondansetron","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4595","Name":"Ondansetron","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/667538","Name":"(-)-Ondansetron","Sub":true}]},{"Name":"ChemSpider","Urls":[{"Link":"https://www.chemspider.com/Chemical-Structure.4434.html","Name":"Ondansetron","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL46","Name":"Ondansetron","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL428411","Name":"(-)-Ondansetron","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7773","Name":"Ondansetron","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=99614-02-5","Name":"Ondansetron","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=99614-60-5","Name":"(-)-Ondansetron","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005035","Name":"Ondansetron","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07325","Name":"Ondansetron","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4AF302ESOS","Name":"Ondansetron","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/8KTH918W9P","Name":"(-)-Ondansetron","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8023393","Name":"Ondansetron","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID20244166","Name":"(-)-Ondansetron","Sub":true}]}],"SMILES":"CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["NMH84OZK2B"],"Solubility":"Sparingly soluble in water","Stability/Shelf Life":"Stable under recommended storage conditions. /Ondansetron hydrochloride dihydrate/","StereoisomerRacemic":"(RS)-Ondansetron","Stereoisomers":["(-)-Ondansetron"],"StereoisomersUNII":["8KTH918W9P"],"StoreUNII":["4AF302ESOS"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="68.469mm" version="1.2" viewBox="0 0 121.849 68.469" width="121.849mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="69.0" stroke="none" width="122.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="94.952" x2="102.548" y1="28.767" y2="41.979"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="114.299" x2="102.548" y1="43.195" y2="41.979"/>
                        
                <line x1="114.048" x2="104.046" y1="45.621" y2="44.585"/>
                      
                <line class="hi" stroke="#3050F8" x1="114.299" x2="108.4235" y1="43.195" y2="42.587"/>
                <line class="hi" stroke="#3050F8" x1="114.048" x2="109.047" y1="45.621" y2="45.103"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="118.447" x2="120.811" y1="47.36" y2="58.445"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="107.676" x2="120.811" y1="66.025" y2="58.445"/>
                        
                <line x1="107.981" x2="118.056" y1="63.034" y2="57.22"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="107.676" x2="99.256" y1="66.025" y2="58.543"/>
                  
            <line class="bond" id="mol1bnd6" x1="102.548" x2="97.95" y1="41.979" y2="52.162"/>
                  
            <line class="bond" id="mol1bnd7" x1="92.958" x2="81.363" y1="56.594" y2="59.066"/>
                  
            <line class="bond" id="mol1bnd8" x1="81.363" x2="71.158" y1="59.066" y2="47.748"/>
                  
            <line class="bond" id="mol1bnd9" x1="71.158" x2="75.832" y1="47.748" y2="33.219"/>
                  
            <line class="bond" id="mol1bnd10" x1="75.832" x2="65.672" y1="33.219" y2="21.941"/>
                  
            <line class="bond" id="mol1bnd11" x1="65.672" x2="50.737" y1="21.941" y2="25.091"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="50.737" x2="46.063" y1="25.091" y2="39.62"/>
                        
                <line x1="52.625" x2="48.814" y1="27.185" y2="39.03"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="46.063" x2="56.223" y1="39.62" y2="50.897"/>
                  
            <line class="bond" id="mol1bnd14" x1="71.158" x2="56.223" y1="47.748" y2="50.897"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="57.6" x2="53.905" y1="50.607" y2="61.952"/>
                        
                <line x1="55.281" x2="51.587" y1="49.852" y2="61.197"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="53.905" x2="55.7525" y1="61.952" y2="56.2795"/>
                <line class="hi" stroke="#FF0D0D" x1="51.587" x2="53.434" y1="61.197" y2="55.5245"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="46.063" x2="30.823" y1="39.62" y2="39.62"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="20.663" x2="30.823" y1="50.897" y2="39.62"/>
                        
                <line x1="19.792" x2="28.072" y1="48.221" y2="39.03"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="20.663" x2="5.728" y1="50.897" y2="47.748"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="1.054" x2="5.728" y1="33.219" y2="47.748"/>
                        
                <line x1="3.805" x2="7.616" y1="33.808" y2="45.654"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="1.054" x2="11.214" y1="33.219" y2="21.941"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="26.15" x2="11.214" y1="25.091" y2="21.941"/>
                        
                <line x1="24.262" x2="12.086" y1="27.185" y2="24.617"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="30.823" x2="26.15" y1="39.62" y2="25.091"/>
                  
            <line class="bond" id="mol1bnd23" x1="26.15" x2="35.37" y1="25.091" y2="18.385"/>
                  
            <line class="bond" id="mol1bnd24" x1="50.737" x2="41.516" y1="25.091" y2="18.385"/>
                  
            <line class="bond" id="mol1bnd25" x1="38.443" x2="38.443" y1="12.3" y2=".91"/>
                  
            <path class="atom" d="M119.573 45.99h-.72l-2.619 -4.066h-.03q.012 .238 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.017 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M98.209 58.338h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M53.763 65.385q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM49.9 65.385q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.386 -.536 .386 -1.459q.0 -.928 -.386 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M40.384 18.6h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm21" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="118.447" x2="119.629" y1="47.36" y2="52.9025"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="99.256" x2="103.46600000000001" y1="58.543" y2="62.284000000000006"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="97.95" x2="100.249" y1="52.162" y2="47.070499999999996"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="92.958" x2="87.1605" y1="56.594" y2="57.83"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="35.37" x2="30.759999999999998" y1="18.385" y2="21.738"/>
            <line class="hi" id="mol1bnd24" stroke="#3050F8" x1="41.516" x2="46.1265" y1="18.385" y2="21.738"/>
            <line class="hi" id="mol1bnd25" stroke="#3050F8" x1="38.443" x2="38.443" y1="12.3" y2="6.605"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ondansetron is included in the database.","Title":"Ondansetron","UNII":"4AF302ESOS","Wikidata":"Q410011","XLogP":2.3}